Understanding Myasthenia Gravis
Myasthenia gravis is a medical condition where the body produces antibodies that attack acetylcholine receptors. This results in muscle weakness and fatigue as the main symptoms. If left untreated, this disease can eventually lead to the destruction of the neuromuscular junction.
Fortunately, there are medications available to help manage this condition. Physicians often prescribe medications that inhibit the enzyme acetylcholinesterase. This enzyme is responsible for breaking down acetylcholine in the body. By inhibiting acetylcholinesterase, doctors can increase the amount of time acetylcholine has to interact with its receptors, helping to alleviate the symptoms associated with myasthenia gravis.
Discovery of Acetylcholine
The groundbreaking discovery of acetylcholine was made in 1914 by Henry Hallett Dale, a renowned English pharmacologist and physiologist. Working alongside his colleague Otto Loewi, Dale established acetylcholine as the first identified neurotransmitter, a finding that would revolutionize the field of neuroscience. Recognizing the significance of their breakthrough, Dale and Loewi were jointly awarded the Nobel Prize for Medicine in 1936.
During their experiments, Loewi initially referred to acetylcholine as “vagusstoff,” as its discovery occurred while studying the effects of the neurotransmitter on the vagus nerve. At the time, Loewi and Dale believed that acetylcholine’s primary function was to regulate heart rate. However, subsequent research would reveal the vast array of roles that acetylcholine plays in the central and peripheral nervous systems.